< Back to Article

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial

Table 2

Humoral and cellular responses by study arm in the per-protocol cohort at the different time points.

doi: https://doi.org/10.1371/journal.pgph.0001308.t002